Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Nov 30;2018(1):161-167.
doi: 10.1182/asheducation-2018.1.161.

The argument for using imatinib in CML

Simone Claudiani  1   2 , Jane F Apperley  1   2
Affiliations
Review

The argument for using imatinib in CML

Simone Claudiani et al. Hematology Am Soc Hematol Educ Program. .

Abstract

June 2018 was the 20th anniversary of the clinical use of the first tyrosine kinase inhibitor (TKI), imatinib, for chronic myeloid leukemia. Since then, the change in prognosis for patients with this disease is one of the major success stories of modern cancer medicine. The dilemmas that face physicians and patients are no longer only those concerned with delaying inevitable progression to the terminal blastic phase or selecting the individuals most likely to benefit from allogeneic stem-cell transplantation; rather, they are now focused also on the choice of TKI, the management of comorbidities and adverse effects, strategies to improve quality of life, and the appropriateness of a trial of therapy discontinuation. Interestingly, with 4 TKIs approved for frontline use, the choice of initial therapy continues to cause controversy, a situation made more complicated by the tantalizing prospect of treatment-free remission. In this manuscript, we will explore the factors influencing this decision and try to provide a pragmatic and clinically applicable solution.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: S.C. declares no competing financial interests. J.F.A. is on the advisory committee for Incyte, Novartis, and Pfizer; has received research funding from Incyte, Novartis, and Pfizer; and has been affiliated with the speaker’s bureau for Bristol Myers Squibb, Incyte, Novartis, and Pfizer.

References

    1. Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34(24):2851-2857. - PubMed
    1. Sasaki K, Strom SS, O’Brien S, et al. . Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015;2(5):e186-e193. - PMC - PubMed
    1. Saussele S, Krauss MP, Hehlmann R, et al. ; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung and the German CML Study Group. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Blood. 2015;126(1):42-49. - PMC - PubMed
    1. Ota S, Matsukawa T, Yamamoto S, et al. . Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia. Eur J Haematol. 2018;101(1):95-105. - PubMed
    1. Etienne G, Guilhot J, Rea D, et al. . Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2017;35(3):298-305. - PubMed

Publication types

MeSH terms

Substances